Complex humoral immune response against a benign tumor: Frequent antibody response against specific antigens as diagnostic targets
Complex humoral immune response against a benign tumor: Frequent antibody response against specific antigens as diagnostic targets
复制标题
DOI：
10.1073/pnas.0500404102
复制
发表时间：
2005-07-05
影响因子：
11.1
通讯作者：
Meese, E
中科院分区：
文献类型：
--
作者：
Comtesse, N;Zippel, A;Meese, E
关于针对人类恶性肿瘤的免疫反应有许多研究。这项研究旨在解决针对良性人类肿瘤的体液免疫反应的复杂性和特异性。我们组装了一组 62 种脑膜瘤表达的抗原，这些抗原与脑膜瘤患者的血清抗体具有反应性，其中包括 41 种以前通过胎儿脑表达库筛选而未表征的抗原。我们测试了该试剂盒与 48 种血清的反应性，其中分别包括普通型、非典型型和间变性脑膜瘤患者的血清。脑膜瘤血清平均每份血清检测到 14.6 个抗原，正常血清每份血清平均检测到 7.8 个抗原 (P = 0.0001)。我们发现恶性肿瘤的血清反应性下降，普通型脑膜瘤和间变性脑膜瘤之间存在统计学显着差异（P < 0.05）。我们仅在患者血清中检测到 17 种抗原，包括 12 种针对 KIAA1344 具有反应性的血清，9 种针对自然杀伤肿瘤识别 (NKTR) 反应的血清，以及 7 种针对 SRY（性别决定区 Y）-box2 (SOX2) 反应的血清。超过 80% 的脑膜瘤患者具有针对至少一种抗原 KIAA1344、SC65、SOX2 和 C6orf153 的抗体。我们的结果显示，针对良性肿瘤的高度复杂但特异性的体液免疫反应具有独特的血清反应模式，并且恶性肿瘤的复杂性下降。针对特定抗原的频繁抗体反应为脑膜瘤提供了新的诊断和治疗靶点。我们开发了一种统计学习方法来区分脑膜瘤患者的血清和健康捐赠者的血清。
There are numerous studies on the immune response against malignant human tumors. This study was aimed to address the complexity and specificity of humoral immune response against a benign human tumor. We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library. We tested the panel for reactivity with 48sera, including sera of patients with common-type, atypical, and anaplastic meningioma, respectively. Meningioma sera detected an average of 14.6 antigens per serum and normal sera an average of 7.8 antigens per serum (P = 0.0001). We found a decline of seroreactivity with malignancy with a statistical significant difference between common-type and anaplastic meningioma (P < 0.05). We detected 17 antigens exclusively with patient sera, including 12 sera that were reactive against KIAA1344, 9 against natural killer tumor recognition (NKTR), and 7 against SRY (sex determining region Y)-box2 (SOX2). More than 80% of meningioma patients had antibodies against at least one of the antigens KIAA1344, SC65, SOX2, and C6orf153. Our results show a highly complex but specific humoral immune response against a benign tumor with a distinct serum reactivity pattern and a decline of complexity with malignancy. The frequent antibody response against specific antigens offers new diagnostic and therapeutic targets for meningioma. We developed a statistical learning method to differentiate sera of meningioma patients from sera of healthy donors.